Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1
    UID:
    almafu_BV049674206
    Format: 1 Online-Ressource (VI, 291 p. 37 illus., 34 illus. in color).
    Edition: 1st ed. 2024
    ISBN: 978-3-031-53659-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53658-8
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53660-1
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53661-8
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Cham :Springer Nature Switzerland :
    UID:
    almafu_9961502510902883
    Format: 1 online resource (289 pages)
    Edition: 1st ed. 2024.
    ISBN: 3-031-53659-2
    Content: This book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT). Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities. Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation reveals a picture of effective management of these patients in order to optimize both short- and long-term outcomes of HSCT. It is of considerable interest to all involved or training within this rapidly growing area of cardiology and oncology.
    Note: HSCT at a glance -- Burden of cardiovascular disease in HSCT -- Risk factors and Mechanisms of Cardiotoxicity in HSCT -- Cardiotoxicity of commonly used drugs in HSCT -- Pre-HSCT cardiovascular evaluation -- HSCT in low EF patients -- Arrhythmias and conduction disorders in HSCT -- Coronary and peripheral arterial disease in HSCT -- Thrombotic disease in HSCT -- Pulmonary hypertension in HSCT -- Pericardial disease in HSCT -- Metabolic syndrome in HSCT -- HSCT in patients with cardiac amyloidosis -- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia -- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.
    Additional Edition: ISBN 3-031-53658-4
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    UID:
    edocfu_BV049674206
    Format: 1 Online-Ressource (VI, 291 p. 37 illus., 34 illus. in color).
    Edition: 1st ed. 2024
    ISBN: 978-3-031-53659-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53658-8
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53660-1
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53661-8
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Cham, Switzerland :Springer,
    UID:
    edocfu_9961502510902883
    Format: 1 online resource (289 pages)
    Edition: First edition.
    ISBN: 3-031-53659-2
    Content: This book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT). Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities. Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation reveals a picture of effective management of these patients in order to optimize both short- and long-term outcomes of HSCT. It is of considerable interest to all involved or training within this rapidly growing area of cardiology and oncology.
    Note: HSCT at a glance -- Burden of cardiovascular disease in HSCT -- Risk factors and Mechanisms of Cardiotoxicity in HSCT -- Cardiotoxicity of commonly used drugs in HSCT -- Pre-HSCT cardiovascular evaluation -- HSCT in low EF patients -- Arrhythmias and conduction disorders in HSCT -- Coronary and peripheral arterial disease in HSCT -- Thrombotic disease in HSCT -- Pulmonary hypertension in HSCT -- Pericardial disease in HSCT -- Metabolic syndrome in HSCT -- HSCT in patients with cardiac amyloidosis -- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia -- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.
    Additional Edition: ISBN 3-031-53658-4
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Cham, Switzerland :Springer,
    UID:
    edoccha_9961502510902883
    Format: 1 online resource (289 pages)
    Edition: First edition.
    ISBN: 3-031-53659-2
    Content: This book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT). Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities. Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation reveals a picture of effective management of these patients in order to optimize both short- and long-term outcomes of HSCT. It is of considerable interest to all involved or training within this rapidly growing area of cardiology and oncology.
    Note: HSCT at a glance -- Burden of cardiovascular disease in HSCT -- Risk factors and Mechanisms of Cardiotoxicity in HSCT -- Cardiotoxicity of commonly used drugs in HSCT -- Pre-HSCT cardiovascular evaluation -- HSCT in low EF patients -- Arrhythmias and conduction disorders in HSCT -- Coronary and peripheral arterial disease in HSCT -- Thrombotic disease in HSCT -- Pulmonary hypertension in HSCT -- Pericardial disease in HSCT -- Metabolic syndrome in HSCT -- HSCT in patients with cardiac amyloidosis -- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia -- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.
    Additional Edition: ISBN 3-031-53658-4
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    UID:
    edoccha_BV049674206
    Format: 1 Online-Ressource (VI, 291 p. 37 illus., 34 illus. in color).
    Edition: 1st ed. 2024
    ISBN: 978-3-031-53659-5
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53658-8
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53660-1
    Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-53661-8
    Language: English
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Did you mean 9783030546595?
Did you mean 9783030536596?
Did you mean 9783031086595?
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages